6505--Acamprosate CA EC Tablets

The solicitation for Acamprosate CA EC Tablets under solicitation number 36E79726R0021, issued by the Department of Veterans Affairs through its Nac Pharmaceuticals office in Hines, Illinois, seeks commercial pharmaceutical supplies under a Lowest Price Technically Acceptable (LPTA) procurement strategy. The contract requires the delivery of 33,661 bottles of 333mg extended-release tablets per base year, with four one-year option periods of equal volume, all subject to strict pharmaceutical and packaging standards. The product must be manufactured and packaged in compliance with FDA regulations, USP-NF monographs, current Good Manufacturing Practices (cGMP), and the Drug Supply Chain Security Act (DSCSA), including serialization via a two-dimensional GS1 Data Matrix bar code at the lowest saleable package level and a linear GS1-128, HIBCC, or UPC bar code complying with ANSI/ISO/IEC Grade C quality standards on the unit-of-use bottle. Packaging must exclude glass, feature a child-resistant safety cap, accommodate automated dispensing systems, provide sufficient space for VA labeling over the contractor’s label, and ensure machine-readable bar codes are presented in ladder orientation with adequate quiet zones and human-readable NDC adjacent to the barcode. The contract incorporates standard Federal Acquisition Regulation clauses with VA-specific deviations, including restrictions on subcontractor sales, mandatory business ethics and whistleblower protections, prohibitions on restrictive confidentiality agreements, and requirements regarding contractor responsibility, suspension, debarment, and inverted domestic corporations. A VA-specific small business subcontracting plan is mandatory for contracts exceeding $700,000, and contractors must affirm small business status, UEI and CAGE codes, and manufacturer commitment if not the producer. Proposals must be submitted by May 28, 2026, via email in PDF or Word format with a signed SF-1449, and must include NDCs, facility FEI numbers, and compliance with DSCSA and FDA requirements. Evaluation is strictly based on lowest price among technically acceptable offers, with no discussions anticipated, and all items are subject to inspection at the source facility and acceptance at the delivery destination. The government will process payments through the VA Prime Vendor program, and all performance must occur at FDA-registered facilities, with deliveries governed by FOB origin or destination terms as specified in individual orders. No contract value is yet determinable, as pricing data must be provided by offerors.